Clinical Biospecimen Collection ((NYCBS))

April 21, 2026 updated by: Harry Staszewski, North Shore Hematology Oncology Associates P.C dba New York Cancer and Blood Specialists

New York Cancer and Blood Specialists: Clinical Biospecimen Collection for Research Use

New York Cancer and Blood Specialists(NYCBS) is dedicated to provide world-class, patient-centered, affordable care to patients with cancer and blood disorders in their own communities, close to family and friends. Our vision is a world free of cancer and blood disorders by contributing to the search for cures by offering cutting-edge clinical trials and personalized, state-of-the-art treatments that save and prolong lives. In support of these objectives NYCBS has created a centralized oncology biorepository in tandem with a longitudinal study to support translational research. This study establishes a biological sample bank and associated data reservoir from thousands of cancer patients, high risk populations, and survivors. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. Researchers will then use these samples and information to better understand how cancer affects the body over time in order to formulate new treatments. The information and samples provided will allow the testing of new therapies and aid in the development of new medical treatments.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Research and development of new diagnostics for earlier detection of, and new treatments for diseases require the use of human biological specimens (biospecimens). Through data and insight gained from the evaluation of these collected biospecimens, the aforementioned novel diagnostics and/or treatments can be developed or validated for a variety of diseases. Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors.

The samples and data may be used for genetic research such as: RNA or DNA isolation and analysis, gene and protein expression, diagnostic device and biomarker research, tissue microarray development, laboratory tests and validation tests. The biospecimens may also be used for genome sequencing.

Study Type

Observational

Enrollment (Estimated)

900000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Subjects diagnosed with or suspected of having cancerous disease, or from healthy, normal donors with the goal of aiding in biomarker research, early detection of disease, and development of new devices or therapies.

Description

Inclusion Criteria:

  1. Subjects must be at least 18 years of age
  2. Subjects must be deemed competent by a qualified clinical study researcher to provide legally documented informed consent
  3. Subjects may or may not have active disease at the time of enrollment
  4. Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors.

Exclusion Criteria:

4) Subjects not meeting the inclusion criteria

Additional inclusion and exclusion criteria may exist, specific to individual project plans, for each collection falling under this protocol. These criteria may include genetic mutation status, progression of disease, and prior lines of therapy among others.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Development of Assays, or Novel Diagnostic's and Treatments to Improve the Quality/Quantity of life for diseased individuals.
Time Frame: 10 years
Expedite development of diagnostic assays and/or novel treatments to improve the quality and/or quantity of life for diseased individuals. Samples may also be utilized in the development of commercial diagnostic reagents." Reagents such as RNA, DNA, and proteins may be involved. Use of this genetic information may aid in the development of novel diagnostics and therapies for patients with certain diseases.
10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

North Shore Hematology Oncology Associates P.C dba New York Cancer and Blood Specialists

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 23, 2025

Primary Completion (Estimated)

October 6, 2035

Study Completion (Estimated)

October 6, 2035

Study Registration Dates

First Submitted

April 15, 2026

First Submitted That Met QC Criteria

April 15, 2026

First Posted (Actual)

April 21, 2026

Study Record Updates

Last Update Posted (Actual)

April 24, 2026

Last Update Submitted That Met QC Criteria

April 21, 2026

Last Verified

October 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • WCG Protocol #20253750

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer Risk

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe